Abstract
To describe and bring together recent development in the diagnosis and treatment of both community-acquired and opportunistic fungal infections in the intensive care unit. The past few years have brought major advances to both the diagnosis and treatment of fungal infections. The development of newer therapeutic modalities to supplement existing treatment options includes a new class of antifungal agents, the echinocandins. Newer and improved agents of the azole class have arrived as well as better delineation for the role of liposomal amphotericins. Newer, nonculture-based diagnostic tests have allowed earlier, more timely diagnosis of opportunistic fungal infections, allowing more rapid initiation of therapy. Improved diagnostic tests and newer antifungal agents have been introduced, leading to earlier diagnosis and treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
